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Abstract: Although several tendon-selective genes exist, they are also expressed in other
musculoskeletal tissues. As cell and tissue engineering is reliant on specific molecular markers
to discriminate between cell types, tendon-specific genes need to be identified. In order to accomplish
this, we have used RNA sequencing (RNA-seq) to compare gene expression between tendon,
bone, cartilage and ligament from horses. We identified several tendon-selective gene markers,
and established eyes absent homolog 2 (EYA2) and a G-protein regulated inducer of neurite
outgrowth 3 (GPRIN3) as specific tendon markers using RT-qPCR. Equine tendon cells cultured
as three-dimensional spheroids expressed significantly greater levels of EYA2 than GPRIN3, and
stained positively for EYA2 using immunohistochemistry. EYA2 was also found in fibroblast-like
cells within the tendon tissue matrix and in cells localized to the vascular endothelium. In summary,
we have identified EYA2 and GPRIN3 as specific molecular markers of equine tendon as compared to
bone, cartilage and ligament, and provide evidence for the use of EYA2 as an additional marker for
tendon cells in vitro.
Keywords: horse; tendon; transcriptome; eyes absent homolog 2; G-protein regulated inducer of
neurite outgrowth 3
1. Introduction
Tendinopathy is one of the most frequently diagnosed sports-related injury both in human and
equine athletes [1–3], predominantly affecting energy-storing tendons such as the superficial digital
flexor tendon (SDFT) in horses [3] and the Achilles tendon in humans [4]. The failure to achieve
regeneration of injured tendon tissue is thought to be the result of an inadequate intrinsic cellular
healing response [5,6]. The regenerative approach to tendon healing aims to regenerate tendon tissue
through the application of growth factors or implantation of stem cells [5,7–11]. Indeed, the clinical
use of mesenchymal stem cells (MSCs) to treat horses suffering from tendon injury was introduced
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over 10 years ago [12]. Furthermore, several in vitro and in vivo studies have since been conducted to
evaluate various aspects of stem cell therapy of tendon injury in the horse [13–16]. Since it is known
that the pathophysiology of tendon injury and the healing response are very similar between horses
and humans, the horse also serves as an important model in tendon research [4].
Tissue engineering aims to provide functional biological substitutes of native tissue for potential
clinical applications. This technique primarily involves the harvesting of specific cell types from various
tissue sources, and their expansion under two- or three-dimensional culture conditions prior to their use
in vivo. However, one of the most challenging aspects of this approach is maintaining the cell’s native
differentiation state for long periods in culture. This is most evident in cells cultured using conventional
two-dimensional systems, where differences in cell–cell and cell–extracellular matrix (ECM) contact
is most evident [17]. Determining the fate of cultured cells is most readily achieved by analysing the
expression of specific genetic markers. However, in the case of stem cell-derived tendon cells, this has
been hampered by the lack of tendon-specific markers [7,18]. This is in contrast to other closely related
tissues such as cartilage and bone, where specific molecular markers for chondrogenic and osteogenic
differentiation pathways have been identified [19]. Currently, the majority of tendon-related research
studies rely on the use of molecular markers such as Tenascin-C (TNC), Tenomodulin (TNMD), Scleraxis
(SCX) and genes encoding collagen type I (COL1A1 and COL1A2) as a means by which to discriminate
between tenocytes and other cell lineages. However, several reports now exist, which bring into
question the validity of such genes as markers of tendon tissue [19–22]. In order to help better identify
more specific tendon markers, gene expression profiling techniques such as microarray analysis
have been used, and identified TNMD and thrombospondin 4 (THBS4) as possible tendon-selective
gene markers [23]. Recent developments in next generation sequencing now offer the possibility to
profile the entire transcriptome in a very high-throughput, accurate and quantitative manner [24].
This technique has been used in equine musculoskeletal tissue to determine transcriptomic signatures
associated with ageing in cartilage [25]. More recently, Peffers et al. described the use of RNA-seq in
tendon for the purpose of studying differentially expressed genes in young versus old macroscopically
normal human Achilles tendons [26]. We hypothesize that it is possible to identify specific genetic
markers of horse tendon tissue using deep-sequencing technology. To this end, we compared gene
expression patterns in various equine musculoskeletal tissues using genome-wide RNA-seq. Molecular
signatures of cultured cells were also considered and compared to the corresponding native tissue.
2. Materials and Methods
2.1. Animals
Tissues samples were harvested from a total of six horses (Table 1). All horses were free from
any previous history of orthopaedic disease and were slaughtered for reasons unrelated to this study.
All tissue specimens used in this study were obtained following owner informed consent and were
harvested in accordance with institutional guidelines and the Swiss animal protection law.
Table 1. Details of horses used in study.
Code Breed Sex Age (years)
Studies Performed
Cell Isolation RNA-seq RT-qPCR
1 Warmblood Mare 6
√ √
2 Warmblood Gelding 4
√ √
3 Warmblood Gelding 3
√ √
4 Lipizzaner Gelding 11
√
5 Warmblood Mare 15
√
6 Warmblood Mare 5
√
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2.2. Sample Collection and Processing
The following tissue samples were collected under aseptic conditions immediately after euthanasia
or slaughter: tendon from the forelimb region of the SDFT; ligament from the collateral ligaments of the
metacarpophalangeal (MCP) joint; cancellous bone from the distal metaphysis of the third metacarpal
bone; cartilage from the articular surfaces of the MCP joint; and cervical dermal tissue. Portions of
the harvested tissue were then placed in RNAlater (Qiagen, Hombrechtikon, Switzerland) and stored
at −80 ◦C, or enzymatically digested for the purpose of isolating tissue specific cells.
2.3. Cell Isolation and Culture
Tendon: Following the removal of the peritenon, tendon sections were cut into 2 mm3 pieces and
subjected to enzymatic digestion with 0.2% collagenase I and 0.3% Dispase II (Roche Diagnostics,
Rotkreuz, Switzerland) on an orbital shaker at 37 ◦C overnight [27]. The isolated tenocytes
were cultured in flasks with Dulbecco’s modified eagle medium (DMEM) supplemented with
10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (all from Thermo Fisher Scientific,
Reinach, Switzerland).
Bone: Pieces of cancellous bone were harvested with a curette and subjected to enzymatic digestion
with 0.1% collagenase II and 0.2% trypsin (BioConcept, Allschwil, Switzerland) at 37 ◦C on an orbital
shaker for 1.5 h. The digested bony pieces were placed in a Petri dish containing bone culture
medium consisting of DMEM/F-12 medium supplemented with 10% FBS, 1% penicillin/streptomycin,
0.2% Amphotericin B (Thermo Fisher Scientific) and 0.5 µg/mL ascorbic acid (Sigma Aldrich, Buchs,
Switzerland) [28]. Isolated cells were transferred to culture flasks containing the bone culture medium
as described above.
Cartilage: Cartilage samples were cut into 2 mm3 pieces and subjected to enzymatic digestion
using 0.1% collagenase II and 0.2% trypsin at 37 ◦C for 3 h. Isolated chondrocytes were then seeded
at a density of 1 × 105 cells/cm2 in cell culture flasks containing DMEM/F-12 culture medium
supplemented with 10% FBS and 1% penicillin/streptomycin.
Dermis: For the isolation of dermal fibroblasts, skin samples were collected and the subcutaneous
fat layer separated. Skin was cut into small fragments of approximately 1 cm2 using sterile forceps
and scissors. The tissue fragments were transferred to a 10 cm tissue culture dish and fibroblasts
were allowed to migrate out for up to a week in DMEM supplemented with 10% FBS and 1%
penicillin/streptomycin. Cells were collected when 80%–90% confluent.
All cell cultures were incubated at 37 ◦C, 5% CO2, under normoxic conditions and passaged twice
upon reaching 90% confluency.
2.4. RNA Isolation
Cells were lysed in RLT buffer (Qiagen) and homogenized using a QIAshredder (Qiagen). Frozen
tissue samples were mechanically crushed under liquid nitrogen, and homogenates were treated with
RTL Buffer (tendon, ligament and cartilage) or TRIzol (bone fragments). RNA was then extracted from
all samples using an RNeasy Mini Kit (Qiagen) and quality was determined using the Agilent 2200
Tape station system and the Agilent Bioanalyzer 2100 (Agilent, Waldbronn, Germany). RNA Integrity
Number (RIN) values for cultured cells and tissue samples were 9.1–9.4 and 6.8–8.1, respectively.
2.5. Illumina RNA Sequencing and Data Analysis
Library preparation: The quality of the isolated RNA was determined using a Qubit® (1.0)
Fluorometer (Life Technologies, Carlasbad, CA, USA) and a Bioanalyzer 2100 (Agilent, Waldbronn,
Germany). Only those samples with a 260/280 nm ratio between 1.8 and 2.1 and a 28S/18S ratio within
1.5 and 2 were further processed. The TruSeq RNA Sample Prep Kit v2 (Illumina, Inc., San Diego, CA,
USA) was used in the subsequent steps. Briefly, total RNA samples (100–1000 ng) were ribo-depleted
using Ribo Zero Gold (Epicentre®, Madison, WI, USA) and then fragmented. The fragmented samples
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were reverse transcribed to cDNA, end-repaired and polyadenylated before ligation of TruSeq adapters
containing the index for multiplexing. Fragments containing TruSeq adapters on both ends were
selectively enriched by PCR. The quality and quantity of the enriched libraries were validated using
Qubit® (1.0) Fluorometer and the Caliper GX LabChip® GX (Caliper Life Sciences, Inc., Hopkinton, MA,
USA). The product is a smear with an average fragment size of approximately 260 bp. The libraries
were normalized to 10 nM in Tris-Cl 10 mM, pH 8.5 with 0.1% Tween 20.
Cluster Generation and Sequencing: The TruSeq PE Cluster Kit v4-cBot-HS or TruSeq SR
Cluster Kit v4-cBot-HS (Illumina, Inc.) was used for cluster generation using 10 pM of pooled
normalized libraries on the cBOT. Sequencing was performed on the Illumina HiSeq 2500 paired
end at 2 × 101 bp or single end 100 bp using the TruSeq sequencing by synthesis (SBS) Kit v4-HS
(Illumina, Inc.). Original data is available at BioProject (www.ncbi.nlm.nih.gov/bioproject/) Accession
Nr. PRJNA343028/SRP091965. Data Analysis: The raw reads were first cleaned by removing adapter
sequences, trimming low quality ends, and filtering reads with low quality (phred quality < 20) using
Trimmomatic [29]. Sequence alignment of the resulting high-quality reads to the Equus Caballus
reference genome (Ensemble v74) was performed with tophat (version 2.0.14) and gene-level counting
with HTSeq (version 0.6.1). Sequencing reads have been scanned with fastqc software and did not show
quality deviations that would prohibit further analysis. To detect differentially expressed genes, we
applied a count based negative binomial model implemented in the software package DESeq [30,31].
Genes showing altered expression with adjusted (Benjamini and Hochberg method) p-value < 0.05 were
considered as differentially expressed (Supplemental Table S1). Process and pathway analysis were
performed with Metacore database via GeneGo tool (Thomson Reuters, http://portal.genego.com) [32].
The pathways (groups of genes belonging to the same pathway map in GeneGo Metacore database:
https://portal.genego.com/) were selected on the basis of the relevance to various biological processes
(Treshold = 2; p-Treshold = 0.05).
2.6. Validation of RNA-seq
Candidate genes identified by RNA-seq were further validated using RT-qPCR. RNA (0.5 µg)
was treated with Turbo DNase (Thermo Fisher Scientific) and reverse transcribed using Oligo-dT
primers and Superscript III (Thermo Fisher Scientific). Real-time PCR was performed in triplicates
with SYBR green (Qiagen) using a Rotor-Gene Q RG-6000 (Qiagen). Data was normalized to 18S
and presented as 2−∆CT. Primer design was performed using the NCBI primer designing tool (http:
//www.ncbi.nlm.nih.gov/tools/primer-blast/) on the Equus caballus (taxid:9796) genome. Primer
pairs were selected based on the presence of at least one intron on the corresponding genomic DNA.
Oligonucleotide primers used in qPCR are listed in Supplementary Table S2.
2.7. Equine Tenocyte Microtissues
In order to generate equine tenocyte microtissues, cells were adjusted to 2 × 105 cells/mL in
normal growth medium and transferred to a reagent reservoir. A total of 25 µL cell suspension was
then transferred to individual wells of a Terasaki plate (VWR International, Dietikon, Switzerland)
using a multistep pipette. When all wells had been filled, lids were mounted and plates inverted in
order to allow for gravity-enforced microtissue formation as previously described [27,33]. After 6 days
of culture, microtissue pellets were harvested and either fixed in 4% paraformaldehyde and processed
for paraffin embedding, or lysed in RTL Buffer (Qiagen) and processed for gene expression analysis as
described above.
2.8. Immunohistochemical Staining
Immunohistochemical analysis of EYA2 and chondrolectin (CHODL) was performed on
rehydrated paraffin wax tissues sections (5 µm) taken from equine tenocyte microtissues and native
equine tendon. Antigen retrieval was performed on native tendon tissue by incubating sections at 98 ◦C
in citrate buffer (pH 6.0) for 15 min. Endogenous biotin and peroxidase activity were controlled for
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using avidin and biotin (Abcam, Cambridge, UK) and 3% hydrogen peroxide, respectively. Sections
were then washed and blocked with 10% normal swine serum for 30 min and incubated with
polyclonal rabbit anti-EYA2 (1 µg/mL; Abcam, UK) or polyclonal rabbit anti-CHODL (2.5 µg/mL;
Biorbyt, Cambridge, UK) overnight at 4 ◦C or for 1 h at 37 ◦C. Tissue sections were also incubated
with equivalent concentrations of a rabbit IgG antibody (Peprotech, London, UK) to control for
non-specific staining. Sections were then washed in PBS and incubated with biotinylated swine
anti-rabbit IgG (1:400; DAKO, Baar, Switzerland) for 1 h at room temperature followed by washing
and further incubation for 30 min with Vectastain (Reactolab SA, Servion, Switzerland). Sections were
then developed using 3,3′-diaminobenzidine tetrahydrochloride (DAB), counterstained with Harris’s
Hematoxylin and mounted in Mowiol.
2.9. Statistical Analysis
One-way analysis of variance (ANOVA) followed by Tukey’s post-hoc test was performed for
multiple group comparisons using SPSS19.0 (SPSS Inc., Chicago, IL, USA). In all cases, a p-value of
<0.05 was considered statistically significant.
3. Results
Tissue engineering aims to provide functional biological substitutes of native tissue for potential
clinical applications. Monolayers of adherent cells grown on flat and rigid two-dimensional substrates
represent the conventional cell culture system, but one of the most challenging aspects of this approach
is the incapacity of in vitro cultured cells to emulate the in vivo conditions. We therefore aimed to
identify specific tendon markers, which could be used to discriminate between cartilage, bone and
ligament, and help monitor the differentiation status of cultured tendon cells.
Bone, cartilage, ligament and tendon tissue were harvested from young adult Warmblood horses
and in the case of tendon, tissue quality was confirmed by macroscopic and histological evaluation [34]
(Supplementary Figure S1). Immediately following their collection, tissues were either directly used
for RNA isolation or for the isolation of osteoblasts, chondrocytes, or tenocytes. Monolayer cultures
were generated from cells extracted from tissues either by spontaneous outgrowth (e.g., osteoblasts),
or by enzymatic digestion (e.g., chondrocytes, tenocytes) (Figure 1A), and RNA isolated for use
in RNA-seq analysis once cells reached confluency. Dermal fibroblasts were also included as a
representative non-musculoskeletal tissue-derived mesenchymal cell. A transcriptomic analysis
was performed by comparing native and in vitro expanded cells. Principal component analysis
confirmed a good separation between most of the tissue types (Figure 1B). Hierarchical clustering of
the top 2000 genes demonstrated an obvious divergence in the clustering of RNA-seq data profiles
between cultured cells and their tissue of origin (Figure 1C). The gene-level summaries have been
added in the supplementary data (Supplementary Table S1), and the data is available at BioProject
(www.ncbi.nlm.nih.gov/bioproject/; Accession Nr. PRJNA343028). A total of 21,733 from more than
28,000 genes tested were expressed in at least one sample. Due to the fact that a significant proportion
of genes continued to pass the adjusted p-value threshold of 5% (also meaning 5% of false positives
estimate) upon statistical filtering, we elected to define the main condition as the fold change (logFC > 2
corresponding to FC = 4). An overview of the number of differentially upregulated and downregulated
genes between tissues is depicted in Figure 1D,E.
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cultured tendon cells; Fc, cultured fibroblasts; Cc, cultured cartilage cells; Bn, native bone; Tn, native 
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native ligamen . 1, 2 and 3 refer to the codes of the ifferent hors s ( = 3) u ed in the study.
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To gain additional insights, we performed functional annotation clustering of differentially
expressed genes by Gene Ontology (GO) using the GeneGO tool. This tool allows analyses to be
performed based on the translation of horse genes (which are still not completely annotated) to their
mouse homologs. The pathway annotations in GeneGo included three times fewer genes (~4500)
than the Gene Ontology annotations (~15,000) thus, increasing the reliability of the Gene Ontology,
especially in the case of homolog translation between species. The main processes identified in native
tissues samples were cellular component organization and metabolism (Figure 2A), whereas in cultured
cells, the cell cycle related processes, cell adhesion and transcription were most prominent (Figure 2B).
These data demonstrate that the cultivation of primary cells (tenocytes, osteoblasts, and chondrocytes)
under the in vitro conditions used in the current report, leads to a substantial shift in their expected
gene expression signature, and are suggestive of functional differences between native and cultured
cell populations. Further analyses were therefore performed using native tissues only, and primarily
focused on identifying tendon specific markers.
Pairwise comparisons made between the different tissue samples identified 21 candidate genes
that were either over-represented or under-represented in tendon tissue as compared to ligament, bone
or cartilage (Figure 2C). In order to further investigate the specificity of these genes with regards to
their expression in tendon, RT-qPCR was performed on RNA from a more diverse group of horses. We
identified 12 genes that were selectively expressed in either tendon (THBS4, TENM4, SCX, ENPEP),
ligament (TNMD), bone (BTLN9, CD36, MASP2, SNCG), or cartilage (CHODL, ACAN, THBS3), and
two genes that were exclusively expressed in tendon (EYA2 and GPRIN3) (Figure 3). These data
therefore confirm EYA2 and GPRIN3 as specific markers of equine tendon as compared to ligament,
bone and cartilage.
In order to further validate the use of EYA2 and GPRIN3 as markers of equine tendon, we
also examined their expression levels in equine tenocytes cultured as three dimensional microtissue
spheroids—an in vitro system known to help maintain the tenocyte phenotype [27]. EYA2 expression
levels were significantly increased in equine tenocyte microtissue spheroids as compared to GPRIN3
(p = 0.001) and the selective cartilage marker CHODL (p = 0.004) (Figure 4A). These observations were
also confirmed at the protein level, where immunohistochemical staining for EYA2 was noticeably
increased in equine tenocyte microtissues as compared to CHODL (Figure 4B). Immunohistochemical
analysis of EYA2 was also performed in native equine tendons, and demonstrated positive EYA2
staining in fibroblast-like cells within the tendon tissue matrix (Figure 4C) and cells localized to the
vascular endothelium (Figure 4D).
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Figure 2. (A,B) Top ten biological process gene ontology terms as determined using GeneGo. Genes 
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cartilage (Cn). 
Figure 2. (A,B) Top ten biological process gene ontology terms as determined using GeneGo. Genes
regulated in native tissues (A) and cultured primary cells (B). (C) Comparison of changes in expression
of 21 selected genes (logFC) between native tendon (Tn), bone (Bn), ligament (Ln) and cartilage (Cn).
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Figure 3. RT-qPCR analysis of candidate genes identified using RNA-seq. Data were normalized to
18S and presented as 2−∆CT. * p < 0.01 as deter ined using one- ay A VA and Tukey post-hoc test.
Data are representative of three separate reactions performed using RNA isolated from three horses.
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Figure 4. (A) Expression levels of EYA2, CHODL and GPRIN3 in equine tenocyte microtissue
was determined using RT-qPCR. Data were normalized to 18S and presented as 2−∆CT* p < 0.01
as determined using one-way ANOVA and Tukey post-hoc test. Data are representative of three
separate reactions; (B) I unohistoche ical analysis of EYA2 and C ODL in equine tenocyte
icrotissues. Paraffin wax sections of equine tenocyte icrotissues ere incubated ith an
anti-EY 2 antibody (top panel) or anti- L antibody (lo er panel) and positive staining
i entifie sing an a ro riate -labelle olyclonal antibo y ith s bseq ent evelo ent
si 3,3′-dia inobenzidine (brown). Specificity was confirmed using the relevant IgG controls. Scale
bar = 100 µm; (C,D) Immunohistoc emical analysis of EYA2 in equine native tendon. Paraffin wax
sections of equine tendon tissue were incubated with an anti-EYA2 tibody and positive staining was
identified using a appropriate HRP-labelled polyclonal antibody with subsequent development using
3,3′-diaminobenzidine (brown). C, Ten inocytes; D Endotendineum. Specificity was confirmed using a
relevant IgG control. Scale b r in all pa els = 50 µm.
4. Discussion
To date, only one study has compared gene expression of equine tendon with that of bone
and cartilage [19]. Although significant increases in SCX were evident in tendon as compared to
bone, no significant differences were observed in comparison to cartilage. Furthermore, TNMD as
expressed at co parable levels in tendon and bone. Therefore, the standard markers currently used to
select for tendon may not be an appropriate choice for use in horses. In order to address this issue,
e used R A-seq and RT-qPCR to co pare gene expression in equine tendon, bone, cartilage and
liga ent tissues, and to further identify changes in the genotype of tissue-specific cells in culture.
RNA-seq demonstrated clustering of characteristic gene expression patterns according to the types
of tissues, and good reproducibility between biological replicates. However, noticeable differences
were observed in gene expression patterns between cultured cells and their respective tissue of
origin. One possible explanation for this might be that the cultured cells underwent dedifferentiation,
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resulting in loss of the native genotype. Certainly, culturing primary cells as monolayers promotes
dedifferentiation and is dependent on passage number [35]. Therefore, although we used cells at a low
passage number, they were cultured as monolayers, which most likely influenced their gene expression
pattern as compared to native tissues. Of note is that gene expression patterns in cultured cells from
tendon, bone and cartilage were comparable to those observed in dermal fibroblasts. Future studies
using primary cells cultured under three-dimensional (3D) conditions might provide further insights
into how dedifferentiation influences gene expression [27].
RNA-seq analysis of tendon, bone, cartilage and ligament tissues revealed numerous differentially
expressed gene candidates. Further validation using RT-qPCR confirmed EYA2 and GPRIN3 as
tendon-specific genes. All the other candidate genes were expressed in more than one tissue,
and therefore not considered suitable for use as specific markers for tendon. Importantly, we were
unable to confirm tendon-specific expression of TNMD, SCX, or THSB4.
Expression of EYA genes, homologues of the eyes absent gene of Drosophila, has previously
been described during limb tendon development [36]. Both EYA1 and EYA2 are widely expressed in
various tissues during organogenesis and act as transcriptional activators [36]. They are also expressed
early on in limb development in connective tissue precursor cells [36]. In later embryologic stages,
both genes are expressed in cell condensations that form different limb tendons [36]. GPRIN3 is
a homologue of GPRIN1, a member of the GPRIN family of proteins involved in the downstream
transduction of signals mediated via G protein coupled receptors (GPRCs) [37]. Ligands binding to
GPRCs catalyse the GDP–GTP exchange of the G protein [37]. The GTP-bound form of G proteins
α-subunits can then bind to various proteins, such as GPRIN1 and GPRIN2, which ultimately leads
to further downstream signalling [37]. Although the specific role of GPRIN3 in tendon development
and/or function remains to be determined, it is of interest to note that EYA2 can also act as a partner
for G protein α-subunits [38].
Although this study is the first to identify EYA2 and GPRIN3 as specific markers of equine tendon
as compared to bone, cartilage and ligament, previous reports have shown expression of these genes
in musculoskeletal tissue from other species. The expression of both EYA2 and GPRIN3 has already
been confirmed in human tendon tissue using RNA-seq [26]. Microarray analysis performed by
Jelinsky et al. [23] has also confirmed EYA2 expression in human and rat tendon. However, in contrast
to our findings, EYA2 was expressed in bone and cartilage [23]. The different species and methods
of analysis used may help to account for these contradictory findings. Indeed, Marioni et al. have
previously shown that differential expression of genes can be assessed more reliably using RNA-seq
as compared to microarray analysis [39]. Even though our RNA-seq data displayed a rather high
variability in gene expression between different samples—most likely as a result of the diversity
within the group of horses used—EYA2 and GPRIN3 were consistently expressed in tendon tissue
and remained absent from all other tissues tested. This therefore highlights their robustness as
tendon-specific markers.
Results from our in vitro studies using cultured equine tenocytes provided further support for the
use of EYA2 as a tendon marker, although failed to demonstrate any significant differences in expression
levels between GPRIN3 and the non-specific tendon marker, CHODL. Although we have previously
identified the microtissue system as a means by which to help maintain the tenocyte phenotype
in vitro [27], our findings also demonstrated that the spindle-like morphology typically associated
with mature tendon cells was only fully realized when microtissues were embedded in collagen gels.
Gene expression analysis in tenocyte microtissues cultured under conditions more representative
of native tendon may therefore be warranted. In addition to EYA2 gene expression, we were also
able to confirm EYA2 protein expression in equine tendon tissue. Immunohistochemical staining of
paraffin-embedded sections demonstrated positive staining for EYA2 in tenocytes cultured under 3D
cultures, and in elongated fibroblast-like tendon cells in native tendon tissue. Blood vessels within
tendon tissue sections also stained positively for EYA2. Due to anatomical and cellular heterogeneity
of tendon [40,41], additional studies will be required to determine the spatial and temporal expression
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of EYA2 in equine tendon. Finally, although we have presented evidence of EYA2 and GPRIN3 as
specific markers of equine tendon in comparison to bone, cartilage and ligament, investigations are
now needed to assess their expression in other species. Taken together, our data suggest that the
combined use of the newly identified tendon-specific markers EYA2 and GPRIN3 with other more
well established selective markers such as SCX and TNMD, could be an effective means by which to
unambiguously determine the identity of tendon tissues generated in vitro.
5. Conclusions
In conclusion, we have established EYA2 and GPRIN3 as two specific molecular markers of equine
tendon tissue in comparison to bone, cartilage and ligament. Our in vitro data also support the use
of EYA2 as an additional means by which to examine the differentiation status of cultured tenocytes.
Finally, based on the observed differences in gene expression between cultured cells and their tissue of
origin, we surmise that the way in which ex vivo material is processed and maintained in culture may
have important implications for tissue engineering applications.
Supplementary Materials: The following are available online at www.mdpi.com/2073-4425/7/11/97/s1,
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RNA Seq Data, Table S2: Table showing oligonucleotides used in qPCR reactions.
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